Venetoclax plus hypomethylating agents as first salvage therapy for myeloid malignancies relapsing after allogeneic HSCT. - Chiusolo P; Malagola M; Giglio F; Frioni F; Secreto C; Lessi F; D'Amore F; Monella IM; Abbenante M; Marconi G; Nanni J; Maggi R; et al. (Bone marrow transplantation, 2026)